Lifecore Biomedical, Inc. (LFCR): Capital Expenditures
$13.41M
Year ended 2025-05-25
-20.0%
3-year compound annual growth
+1.9%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-05-25 | $13.41M | -27.1% | 2025-08-07, From 2024-05-27 |
| 2024-05-26 | $18.39M | n/a | 2025-08-07, From 2023-05-29 |
| No annual figure between 2022-05-29 and 2024-05-26. | |||
| 2022-05-29 | $26.23M | +36.1% | 2023-03-16, From 2021-05-31 |
| 2021-05-30 | $19.26M | +57.7% | 2023-03-16, From 2020-06-01 |
| 2020-05-31 | $12.21M | -72.7% | 2023-03-16, From 2019-05-27 |
| 2019-05-26 | $44.73M | +33.2% | 2021-07-29, From 2018-05-28 |
| 2018-05-27 | $33.59M | +46.0% | 2020-08-14, From 2017-05-29 |
| 2017-05-28 | $23.00M | -42.1% | 2019-08-01, From 2016-05-30 |
| 2016-05-29 | $39.70M | n/c | 2018-08-09, From 2015-06-01 |
| 2015-05-31 | $17.51M | +17.6% | 2018-03-15, From 2014-05-26 |
| 2014-05-25 | $14.89M | +67.7% | 2016-08-01, From 2013-05-27 |
| 2013-05-26 | $8.88M | +65.3% | 2015-07-31, From 2012-05-28 |
| 2012-05-27 | $5.37M | -19.6% | 2014-08-01, From 2011-05-30 |
| 2011-05-29 | $6.68M | +28.7% | 2013-08-07, From 2010-05-31 |
| 2010-05-30 | $5.19M | n/a | 2012-08-08, From 2009-06-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $13.41M | -27.1% |
| Xencor Inc (XNCR) | 2025-12-31 | $3.15M | -48.3% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $1.19M | -48.6% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $0 | -100.0% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $925.6K | -43.0% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $1.91M | -48.4% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $289.0K | -2.0% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $42.0K | -87.3% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $317.0K | -81.4% |
Compare LFCR, XNCR, GYRE, KPTI side by side · Screen every company in Pharmaceutical Preparations ↗